FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921369621> ?p ?o ?g. }

• W2921369621 endingPage "S353" @default.
• W2921369621 startingPage "S353" @default.
• W2921369621 abstract "Introduction: Treatment goals for ulcerative colitis (UC) focus on inducing a response and maintaining long-term disease remission. The current study sought to document the real-world treatment patterns during the first year of advanced therapy in the US. Methods: This retrospective analysis used Truven MarketScanSymbol Commercial and Medicare Supplemental Database claims data from January 1, 2012 to March 31, 2017. Patients aged ≥18 years with UC (ICD9:556.* or ICD10 K51.* ) naive to advanced therapy who initiated an immunomodulator (IM) or a biologic (adalimumab [ADA], infliximab [IFX], vedolizumab [VEDO], golimumab [GOL]) and had 12 months continuous enrollment prior to (pre-index) and after (post-index) their first drug claim (index) were included. Patients with a diagnosis of Crohn's disease or history of biologic therapy in the pre-index period were excluded. Treatment patterns were reported descriptively, including combination therapy (frequency of an IM with a biologic) and persistence (frequency of patients using their index therapy at the end of the 12-month post-index period without a 60-day gap). Among patients using biologic therapy who had claims containing valid quantity data, dose escalation was also reported (frequency of patients using a higher than indicated dose while persistent during maintenance).SymbolResults: A total of N=3562 patients with UC were included (51.4% male; age=45.1 years (SD=15.1); disease duration=1.3 years (SD=1.2)) with the following treatments at index: N=1231 on an IM without a biologic, N=1291 on ADA, N=810 on IFX, N=127 on GOL, N=103 on VEDO. Use of a concomitant IM therapy occurred as follows: ADA=27.9%, IFX=29.6%, GOL=26.0%, and VEDO=21.4%. Among patients with valid quantity claims, dose escalation during maintenance was observed among 23.6% of ADA, 34.8% of IFX, 9.9% of GOL, and 39.2% of VEDO patients. A total of 60.7% of patients who initiated a biologic therapy remained persistent (i.e., continued on therapy) throughout the 12-month post-index observation period. This varied by therapy: ADA=56.9%, IFX=64.8%, GOL=63.8%, and VEDO=70.9%. Conclusion: For UC patients initiating biologic therapy, 20-30% of patients concomitantly use an IM and 20-40% (except those on GOL) escalate their dose. Nearly 40% of patients discontinue their biologic therapy within the first 12 months. These findings suggest a number of patients experience suboptimal levels of disease control within the first year of advanced therapy." @default.
• W2921369621 created "2019-03-22" @default.
• W2921369621 creator A5007296531 @default.
• W2921369621 creator A5017139774 @default.
• W2921369621 creator A5038198314 @default.
• W2921369621 creator A5059581294 @default.
• W2921369621 creator A5064863811 @default.
• W2921369621 creator A5066450152 @default.
• W2921369621 date "2018-10-01" @default.
• W2921369621 modified "2023-10-18" @default.
• W2921369621 title "Dose Escalation and Treatment Patterns of Advanced Therapies Used to Treat Ulcerative Colitis: A Retrospective Database Analysis in the United States" @default.
• W2921369621 doi "https://doi.org/10.14309/00000434-201810001-00622" @default.
• W2921369621 hasPublicationYear "2018" @default.
• W2921369621 type Work @default.
• W2921369621 sameAs 2921369621 @default.
• W2921369621 citedByCount "2" @default.
• W2921369621 countsByYear W29213696212020 @default.
• W2921369621 countsByYear W29213696212022 @default.
• W2921369621 crossrefType "journal-article" @default.
• W2921369621 hasAuthorship W2921369621A5007296531 @default.
• W2921369621 hasAuthorship W2921369621A5017139774 @default.
• W2921369621 hasAuthorship W2921369621A5038198314 @default.
• W2921369621 hasAuthorship W2921369621A5059581294 @default.
• W2921369621 hasAuthorship W2921369621A5064863811 @default.
• W2921369621 hasAuthorship W2921369621A5066450152 @default.
• W2921369621 hasConcept C126322002 @default.
• W2921369621 hasConcept C167135981 @default.
• W2921369621 hasConcept C2776207728 @default.
• W2921369621 hasConcept C2777138892 @default.
• W2921369621 hasConcept C2778260677 @default.
• W2921369621 hasConcept C2779134260 @default.
• W2921369621 hasConcept C2780132546 @default.
• W2921369621 hasConcept C2780479503 @default.
• W2921369621 hasConcept C2781290027 @default.
• W2921369621 hasConcept C41008148 @default.
• W2921369621 hasConcept C71924100 @default.
• W2921369621 hasConcept C77088390 @default.
• W2921369621 hasConceptScore W2921369621C126322002 @default.
• W2921369621 hasConceptScore W2921369621C167135981 @default.
• W2921369621 hasConceptScore W2921369621C2776207728 @default.
• W2921369621 hasConceptScore W2921369621C2777138892 @default.
• W2921369621 hasConceptScore W2921369621C2778260677 @default.
• W2921369621 hasConceptScore W2921369621C2779134260 @default.
• W2921369621 hasConceptScore W2921369621C2780132546 @default.
• W2921369621 hasConceptScore W2921369621C2780479503 @default.
• W2921369621 hasConceptScore W2921369621C2781290027 @default.
• W2921369621 hasConceptScore W2921369621C41008148 @default.
• W2921369621 hasConceptScore W2921369621C71924100 @default.
• W2921369621 hasConceptScore W2921369621C77088390 @default.
• W2921369621 hasIssue "Supplement" @default.
• W2921369621 hasLocation W29213696211 @default.
• W2921369621 hasOpenAccess W2921369621 @default.
• W2921369621 hasPrimaryLocation W29213696211 @default.
• W2921369621 hasRelatedWork W2006826205 @default.
• W2921369621 hasRelatedWork W2042655884 @default.
• W2921369621 hasRelatedWork W2105263940 @default.
• W2921369621 hasRelatedWork W2138584845 @default.
• W2921369621 hasRelatedWork W2152399325 @default.
• W2921369621 hasRelatedWork W2326143279 @default.
• W2921369621 hasRelatedWork W2327255580 @default.
• W2921369621 hasRelatedWork W2565544404 @default.
• W2921369621 hasRelatedWork W3147462706 @default.
• W2921369621 hasRelatedWork W4213385218 @default.
• W2921369621 hasVolume "113" @default.
• W2921369621 isParatext "false" @default.
• W2921369621 isRetracted "false" @default.
• W2921369621 magId "2921369621" @default.
• W2921369621 workType "article" @default.